Christopher B Fox

List of Publications by Year
in descending order

96 papers	5,968 citations	81743 39 h-index	76769 74 g-index
100 all docs	100 docs citations	100 times ranked	7839 citing authors

#	Article	IF	Citations
1	A molecular atlas of innate immunity to adjuvanted and live attenuated vaccines, in mice. Nature Communications, 2022, 13, 549.	5.8	21
2	A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. Molecular Therapy - Methods and Clinical Development, 2022, 25, 205-214.	1.8	33
3	Early Post-Vaccination Gene Signatures Correlate With the Magnitude and Function of Vaccine-Induced HIV Envelope-Specific Plasma Antibodies in Infant Rhesus Macaques. Frontiers in Immunology, 2022, 13, 840976.	2.2	1
4	Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate. International Journal of Pharmaceutics, 2021, 593, 120121.	2.6	29
5	A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield. Journal of Chromatography A, 2021, 1635, 461705.	1.8	8
6	Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. PLoS ONE, 2021, 16, e0247990.	1.1	20
7	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature, 2021, 594, 553-559.	13.7	199
8	Development of thermostable vaccine adjuvants. Expert Review of Vaccines, 2021, 20, 497-517.	2.0	10
9	Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy. Frontiers in Immunology, 2021, 12, 683157.	2.2	11
10	Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray drying. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 23-37.	2.0	22
11	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nature Communications, 2021, 12, 3587.	5.8	71
12	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology, 2021, 6, .	5.6	34
13	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Science Immunology, 2021, 6, .	5.6	53
14	Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery. Vaccine, 2021, 39, 5025-5036.	1.7	16
15	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant. Npj Vaccines, 2021, 6, 137.	2.9	15
16	Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model. Frontiers in Pharmacology, 2021, 12, 799034.	1.6	6
17	Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells. Nanoscale, 2020, 12, 2515-2523.	2.8	18
18	Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response. Pharmaceuticals, 2020, 13, 168.	1.7	6

#	Article	IF	Citations
19	Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil. PLoS ONE, 2020, 15, e0233632.	1.1	4
20	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelopeâ€“specific plasma cells and humoral immunity in nonhuman primates. Science Immunology, 2020, 5, .	5.6	90
21	Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved In Vitro Th1-Type Cytokine Recall Responses in Human Whole Blood. ACS Omega, 2020, 5, 31306-31313.	1.6	4
22	Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family. Phytomedicine, 2019, 64, 152927.	2.3	10
23	Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. Npj Vaccines, 2019, 4, 1.	2.9	91
24	A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen. Npj Vaccines, 2018, 3, 39.	2.9	14
25	Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. Npj Vaccines, 2018, 3, 51.	2.9	252
26	Correlates of GLA family adjuvantsâ€™ activities. Seminars in Immunology, 2018, 39, 22-29.	2.7	35
27	Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses. Journal of Immunology, 2018, 201, 98-112.	0.4	37
28	Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach. International Journal of Nanomedicine, 2018, Volume 13, 3689-3711.	3.3	35
29	A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. Molecular Therapy, 2018, 26, 2507-2522.	3.7	109
30	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	1.5	39
31	AS03 stresses out macrophages: Commentary on â€˜Activation of the endoplasmic reticulum stress sensor IRE1Î± by the vaccine adjuvant AS03 contributes to its immunostimulatory propertiesâ€™. Npj Vaccines, 2018, 3, 27.	2.9	2
32	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2018, 92, .	1.5	39
33	Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica. Npj Vaccines, 2018, 3, 22.	2.9	29
34	Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine, 2017, 35, 916-922.	1.7	22
35	A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Scientific Reports, 2017, 7, 46426.	1.6	66
36	The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines. Infection and Immunity, 2017, 85, .	1.0	64

#	Article	IF	Citations
37	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	5.8	81
38	Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge. AAPS PharmSciTech, 2017, 18, 2077-2084.	1.5	5
39	Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines. Vaccine, 2017, 35, 5209-5216.	1.7	18
40	Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis. Therapeutic Advances in Vaccines, 2017, 5, 31-38.	2.7	3
41	It is time to accelerate building local vaccine adjuvant manufacturing capacity. , 2017, 5, 111-113.	1.4	3
42	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	5.8	76
43	A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PLoS ONE, 2016, 11, e0149610.	1.1	28
44	A structureâ€function approach to optimizing TLR4 ligands for human vaccines. Clinical and Translational Immunology, 2016, 5, e108.	1.7	44
45	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.4	6
46	Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. Journal of Controlled Release, 2016, 244, 98-107.	4.8	57
47	Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Scientific Reports, 2016, 6, 19570.	1.6	205
48	IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants. Journal of Immunology, 2016, 197, 4351-4359.	0.4	31
49	Molecular Design of Squalene/Squalane Countertypes via the Controlled Oligomerization of Isoprene and Evaluation of Vaccine Adjuvant Applications. Biomacromolecules, 2016, 17, 165-172.	2.6	12
50	Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Human Vaccines and Immunotherapeutics, 2016, 12, 1009-1026.	1.4	12
51	Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen. Vaccine, 2016, 34, 2207-2215.	1.7	37
52	Quantitative Measurement of Toll-like Receptor 4 Agonists Adsorbed to AlhydrogelÂ® by Fourier Transform Infrared-Attenuated Total Reflectance Spectroscopy. Journal of Pharmaceutical Sciences, 2015, 104, 768-774.	1.6	5
53	New generation adjuvants â€“ From empiricism to rational design. Vaccine, 2015, 33, B14-B20.	1.7	126
54	Are we entering a new age for human vaccine adjuvants?. Expert Review of Vaccines, 2015, 14, 909-911.	2.0	24

#	Article	IF	Citations
55	Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine, 2015, 33, 6570-6578.	1.7	53
56	Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, ILâ€18, and IFNâ€Î³. European Journal of Immunology, 2015, 45, 407-417.	1.6	65
57	Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes. International Journal of Nanomedicine, 2014, 9, 1367.	3.3	27
58	Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization. Journal of Controlled Release, 2014, 177, 20-26.	4.8	51
59	In vitro evaluation of TLR4 agonist activity: Formulation effects. Colloids and Surfaces B: Biointerfaces, 2014, 113, 312-319.	2.5	47
60	Modulating Potency: Physicochemical Characteristics are a Determining Factor of TLR4-Agonist Nanosuspension Activity. Journal of Pharmaceutical Sciences, 2014, 103, 879-889.	1.6	7
61	A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7. Journal of Nanobiotechnology, 2014, 12, 17.	4.2	65
62	A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93. PLoS ONE, 2014, 9, e83884.	1.1	60
63	A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate. PLoS ONE, 2014, 9, e107764.	1.1	43
64	An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Review of Vaccines, 2013, 12, 747-758.	2.0	129
65	TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine, 2013, 31, 5848-5855.	1.7	29
66	Working together: interactions between vaccine antigens and adjuvants. Therapeutic Advances in Vaccines, 2013, 1, 7-20.	2.7	90
67	Charged aerosol detection to characterize components of dispersed-phase formulations. Advances in Colloid and Interface Science, 2013, 199-200, 59-65.	7.0	9
68	Key roles of adjuvants in modern vaccines. Nature Medicine, 2013, 19, 1597-1608.	15.2	1,091
69	Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity. Journal of Nanobiotechnology, 2013, 11, 43.	4.2	8
70	Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. Journal of Controlled Release, 2013, 172, 190-200.	4.8	101
71	Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine, 2013, 31, 1633-1640.	1.7	18
72	Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy. Influenza and Other Respiratory Viruses, 2013, 7, 815-826.	1.5	21

#	Article	IF	Citations
73	Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines. Vaccine Journal, 2012, 19, 1633-1640.	3.2	55
74	Adjuvants for Leishmania vaccines: from models to clinical application. Frontiers in Immunology, 2012, 3, 144.	2.2	64
75	Microscopic Rates of Peptideâ€“Phospholipid Bilayer Interactions from Single-Molecule Residence Times. Journal of the American Chemical Society, 2012, 134, 19652-19660.	6.6	27
76	Immunomodulatory and Physical Effects of Phospholipid Composition in Vaccine Adjuvant Emulsions. AAPS PharmSciTech, 2012, 13, 498-506.	1.5	21
77	Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine, 2012, 30, 3311-3319.	1.7	30
78	Characterization of TLR4 Agonist Effects on AlhydrogelÂ® Sedimentation: A Novel Application of Laser Scattering Optical Profiling. Journal of Pharmaceutical Sciences, 2012, 101, 4357-4364.	1.6	16
79	Enhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants. , 2012, , 45-72.		0
80	Confocal Raman microscopy for monitoring the membrane polymerization and thermochromism of individual, optically trapped diacetylenic phospholipid vesicles. Journal of Raman Spectroscopy, 2012, 43, 351-359.	1.2	10
81	Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. Pharmaceutical Development and Technology, 2011, 16, 511-519.	1.1	24
82	Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine, 2011, 29, 644-649.	1.7	33
83	A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 â€“ A GLURPâ€“MSP3 fusion protein malaria vaccine candidate. Vaccine, 2011, 29, 3284-3292.	1.7	59
84	Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine, 2011, 29, 9563-9572.	1.7	59
85	Use of defined TLR ligands as adjuvants within human vaccines. Immunological Reviews, 2011, 239, 178-196.	2.8	356
86	Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant. PLoS ONE, 2011, 6, e16333.	1.1	281
87	Synthetic and Natural TLR4 Agonists as Safe and Effective Vaccine Adjuvants. Sub-Cellular Biochemistry, 2010, 53, 303-321.	1.0	56
88	Confocal Raman microscopy for simultaneous monitoring of partitioning and disordering of tricyclic antidepressants in phospholipid vesicle membranes. Journal of Raman Spectroscopy, 2010, 41, 498-507.	1.2	43
89	Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids and Surfaces B: Biointerfaces, 2010, 75, 123-132.	2.5	97
90	Selfâ€Assembly of a Triangleâ€Shaped, Hexaplatinumâ€Incorporated, Supramolecular Amphiphile in Solution and at Interfaces. Chemistry - A European Journal, 2009, 15, 8566-8577.	1.7	18

#	Article	IF	Citations
91	Single-Molecule Fluorescence Imaging of Peptide Binding to Supported Lipid Bilayers. Analytical Chemistry, 2009, 81, 5130-5138.	3.2	42
92	Squalene Emulsions for Parenteral Vaccine and Drug Delivery. Molecules, 2009, 14, 3286-3312.	1.7	164
93	Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids and Surfaces B: Biointerfaces, 2008, 65, 98-105.	2.5	75
94	Temperature-Controlled Confocal Raman Microscopy to Detect Phase Transitions in Phospholipid Vesicles. Applied Spectroscopy, 2007, 61, 465-469.	1.2	39
95	Detecting Phase Transitions in Phosphatidylcholine Vesicles by Raman Microscopy and Self-Modeling Curve Resolution. Journal of Physical Chemistry B, 2007, 111, 11428-11436.	1.2	116
96	Detection of Drugâ^'Membrane Interactions in Individual Phospholipid Vesicles by Confocal Raman Microscopy. Analytical Chemistry, 2006, 78, 4918-4924.	3.2	68